Jelani C Zarif1, Javier A Baena-Del Valle2, Jessica L Hicks3, Christopher M Heaphy4, Igor Vidal3, Jacob Luo3, Tamara L Lotan3, Jody E Hooper3, William B Isaacs5, Kenneth J Pienta6, Angelo M De Marzo4. 1. The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. Electronic address: jzarif1@jhmi.edu. 2. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pathology and Laboratory Medicine, Fundacion Santa Fe de Bogota University Hospital, Bogota, Colombia. 3. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Oncology, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. 6. The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: M2 tumor-associated macrophages (M2-TAMs) can suppress inflammation in the tumor microenvironment and have been reported to modulate cancer progression. We and others have previously reported M2-TAM infiltration in metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To determine whether the extent of M2-TAM infiltration correlates with PC aggressiveness. DESIGN, SETTING, AND PARTICIPANTS: Normal prostate tissue, localized PC, and mCRPC samples from 192 patients were retrospectively analyzed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We analytically validated an immunohistochemistry assay for detection of the human mannose receptor (CD206) to assess M2 macrophage involvement. RESULTS AND LIMITATIONS: Multiplex immunofluorescent staining showed that a small fraction of CD206 staining co-localized with the endothelial cells of lymphatic vessels, while the vast majority of staining occurred in CD68-positive macrophages. The area fraction of staining for CD206-positive macrophages increased in a stepwise fashion from normal (ie, no inflammation) prostate tissue, to primary untreated carcinomas, to hormone-naïve regional lymph node metastases, to mCRPC. Complementary studies using flow cytometry confirmed CD206-positive M2-TAM infiltration. Limitations include the small number of rapid autopsy samples and the lack of neuroendocrine PC samples. CONCLUSIONS: Our results revealed a progressive increase in CD206-positive macrophages from normal prostate to mCRPC. Given the immunosuppressive nature of macrophages and the lack of clinical success of immunotherapy for PC patients, our results provide a rationale for therapeutic targeting of macrophages in the PC microenvironment as a potential method to augment immunotherapeutic responses. PATIENT SUMMARY: In this report we used 192 prostate cancer samples to determine if M2 macrophage infiltration is correlated with castration resistance in prostate cancer.
BACKGROUND: M2 tumor-associated macrophages (M2-TAMs) can suppress inflammation in the tumor microenvironment and have been reported to modulate cancer progression. We and others have previously reported M2-TAM infiltration in metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To determine whether the extent of M2-TAM infiltration correlates with PC aggressiveness. DESIGN, SETTING, AND PARTICIPANTS: Normal prostate tissue, localized PC, and mCRPC samples from 192 patients were retrospectively analyzed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We analytically validated an immunohistochemistry assay for detection of the humanmannose receptor (CD206) to assess M2 macrophage involvement. RESULTS AND LIMITATIONS: Multiplex immunofluorescent staining showed that a small fraction of CD206 staining co-localized with the endothelial cells of lymphatic vessels, while the vast majority of staining occurred in CD68-positive macrophages. The area fraction of staining for CD206-positive macrophages increased in a stepwise fashion from normal (ie, no inflammation) prostate tissue, to primary untreated carcinomas, to hormone-naïve regional lymph node metastases, to mCRPC. Complementary studies using flow cytometry confirmed CD206-positive M2-TAM infiltration. Limitations include the small number of rapid autopsy samples and the lack of neuroendocrine PC samples. CONCLUSIONS: Our results revealed a progressive increase in CD206-positive macrophages from normal prostate to mCRPC. Given the immunosuppressive nature of macrophages and the lack of clinical success of immunotherapy for PCpatients, our results provide a rationale for therapeutic targeting of macrophages in the PC microenvironment as a potential method to augment immunotherapeutic responses. PATIENT SUMMARY: In this report we used 192 prostate cancer samples to determine if M2 macrophage infiltration is correlated with castration resistance in prostate cancer.
Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: E Gottfried; L A Kunz-Schughart; A Weber; M Rehli; A Peuker; A Müller; M Kastenberger; G Brockhoff; R Andreesen; M Kreutz Journal: Scand J Immunol Date: 2008-05 Impact factor: 3.487
Authors: G Comito; E Giannoni; C P Segura; P Barcellos-de-Souza; M R Raspollini; G Baroni; M Lanciotti; S Serni; P Chiarugi Journal: Oncogene Date: 2013-06-03 Impact factor: 9.867
Authors: Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule Journal: Prostate Date: 2019-12-11 Impact factor: 4.104
Authors: Sudha M Sadasivan; Yalei Chen; Nilesh S Gupta; Xiaoxia Han; Kevin R Bobbitt; Dhananjay A Chitale; Sean R Williamson; Andrew G Rundle; Deliang Tang; Benjamin A Rybicki Journal: Carcinogenesis Date: 2020-08-12 Impact factor: 4.944
Authors: Janielle P Maynard; Jiayun Lu; Igor Vidal; Jessica Hicks; Luke Mummert; Tamirat Ali; Ryan Kempski; Ayanna M Carter; Rebecca Y Sosa; Lauren B Peiffer; Corinne E Joshu; Tamara L Lotan; Angelo M De Marzo; Karen S Sfanos Journal: J Pathol Date: 2021-11-25 Impact factor: 7.996
Authors: Yukiko Yamaguchi; Jackson Gibson; Kevin Ou; Lupita S Lopez; Rachel H Ng; Neena Leggett; Vanessa D Jonsson; Jelani C Zarif; Peter P Lee; Xiuli Wang; Catalina Martinez; Tanya B Dorff; Stephen J Forman; Saul J Priceman Journal: J Immunother Cancer Date: 2022-06 Impact factor: 12.469
Authors: Amber E de Groot; Kayla V Myers; Timothy E G Krueger; Ashley L Kiemen; Natalia H Nagy; Alexandria Brame; Vicente E Torres; Zhongyuan Zhang; Levent Trabzonlu; W Nathaniel Brennen; Denis Wirtz; Angelo M De Marzo; Sarah R Amend; Kenneth J Pienta Journal: Prostate Date: 2021-05-05 Impact factor: 4.012